Budoprutug Biosimilar Monoclonal Antibody (CD19) for Research

Cat No.: GMP-Bios-INN-1115

Anti-CD19 therapeutic antibody (Pre-made Budoprutug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Budoprutug (development code VB119) is a monoclonal antibody targeting CD19. It is developed by ValenzaBio and ACELYRIN for focal segmental glomerulosclerosis. It is in Phase I clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1115-1mg 1mg 3090
GMP-Bios-INN-1115-10mg 10mg
GMP-Bios-INN-1115-100mg 100mg
GMP-Bios-INN-1115-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Budoprutug biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-CD19/B-lymphocyte antigen CD19/B-lymphocyte surface antigen B4/Differentiation antigen CD19 therapeutic antibody
INN Name Budoprutug
Target CD19
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-I
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2023
Year Recommended 2024
Companies ValenzaBio;ACELYRIN
Conditions Approved na
Conditions Active Focal segmental glomerulosclerosis
Conditions Discontinued na
Production na
Development Tech na